Ignite Creation Date:
2024-05-06 @ 1:07 PM
Last Modification Date:
2024-10-26 @ 1:09 PM
Study NCT ID:
NCT03944772
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-14
First Post:
2019-04-29
Brief Title:
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy ORCHARD
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ORCHARD
Brief Summary:
Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy This study is modular in design allowing evaluation of the efficacy safety and tolerability of multiple study treatments
Detailed Description:
This is an open-label multicentre multi-drug biomarker-directed Phase 2 platform study in patients with advanced non-small cell lung cancer NSCLC harbouring an epidermal growth factor receptor EGFR-sensitizing mutation whose disease has progressed on first-line monotherapy with osimertinibTreatment options for these patients are limited Novel treatments for these patients are urgently required
This study is modular in design allowing evaluation of the efficacy safety and tolerability of multiple study treatments
This study is modular in design allowing evaluation of the efficacy safety and tolerability of multiple study treatments
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2018-003974-29 | EUDRACT_NUMBER | None | None |